Developer docs
API playgroundTry for free, no card

Search company profiles

GliaCure

Full company profile

uuid00046io

Namestring
GliaCure
Websiteurl
gliacure.com
Company typeenum
Private
Founded yearint
2011
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersBoston, United States
HQ citystring
Boston
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
glia-targeted therapeutics, neurological disorder drug discovery, neuropsychiatric therapy development, central nervous system treatments, neurodegenerative disease research
Industry1 code
1General Neurology
CodeHLAKAIAAPrimaryYes
NAICS code2 codes
  • Research and Development in the Physical, Engineering, and Life Sciences54171
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Neurological Therapeutics
Social media profiles1 record
Marketing channels1 record

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components3 values
Personnel, Technology or R&D, Operations
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

GliaCure is a biopharmaceutical company that develops therapies for neurological and neuropsychiatric disorders based on glia (glial cell) targets. The company focuses on drug discovery and early-stage development of therapeutics that leverage glial cell biology to treat central nervous system conditions.

Differentiator
Functional benefit
Problem solved
Product and service1 record
1Glia-targeting therapeutic pipeline
CategoryNeurological Therapeutics
Description

Preclinical/early-clinical therapeutic candidates targeting glial cell biology for the treatment of neurological and neuropsychiatric disorders, intended for out-licensing or partnership with pharmaceutical companies.

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight2 records

Each record includes

Type, Description

Market position
Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat2 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights4 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds4 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

GliaCure

Neurological Therapeuticsgliacure.com

GliaCure firmographics

Firmographics
Name
GliaCure
Website
https://gliacure.com
Company type
Private
Founded year
2011
Operating status
Operating
Headcount range
1–10 employees
Ownership category
akta.pro rank

GliaCure industry classification

Industry
Product category
Neurological Therapeutics
NAICS
Research and Development in the Physical, Engineering, and Life Sciences (54171), Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Pharmaceutical Preparations (2834)
akta.pro primary industry
General Neurology (HLAKAIAA)

Keywords

  • Glia-targeted therapeutics
  • Neurological disorder drug discovery
  • Neuropsychiatric therapy development
  • Central nervous system treatments
  • Neurodegenerative disease research

Where GliaCure is headquartered

Location

Headquarters

HQ city
Boston
HQ country
United States
HQ region
North America

Markets served

GliaCure business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations

Distribution channels1 record

Marketing channels1 record

GliaCure product offering

Product offering

Core offering

GliaCure is a biopharmaceutical company that develops therapies for neurological and neuropsychiatric disorders based on glia (glial cell) targets. The company focuses on drug discovery and early-stage development of therapeutics that leverage glial cell biology to treat central nervous system conditions.

Differentiator

Problem solved

Functional benefit

Products and services

  • Glia-targeting therapeutic pipeline Preclinical/early-clinical therapeutic candidates targeting glial cell biology for the treatment of neurological and neuropsychiatric disorders, intended for out-licensing or partnership with pharmaceutical companies.

Companies that use GliaCure

Customer profile

Segments1 record

Ideal customer profiles1 record

GliaCure technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

GliaCure partnerships and signals

Strategic signal

Recent moves5 records

Expansion highlights2 records

GliaCure competitors and assessment

Company assessment

Market position

Weaknesses4 records

Competitive moat2 records

Key risks5 records

Key highlights4 records

Customer concentration

GliaCure social profiles

Digital presence

GliaCure financial estimates

Financial estimate

Revenue estimate

Valuation estimate

GliaCure leadership team

Management profile

Number of profiles

Profiles1 record

GliaCure funding detail

Funding detail

Funding overview

Funding rounds4 records

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

GliaCure M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about GliaCure

What does GliaCure do?

GliaCure is a biopharmaceutical company that develops therapies for neurological and neuropsychiatric disorders based on glia (glial cell) targets. The company focuses on drug discovery and early-stage development of therapeutics that leverage glial cell biology to treat central nervous system conditions.

Is GliaCure a public or private company?

GliaCure is a private company. It is classified as venture growth investor backed and is currently operating.

When was GliaCure founded?

GliaCure was founded in 2011. It employs 1 to 10 people.

Where is GliaCure based?

GliaCure is headquartered in Boston, United States, in the North America region.

Does GliaCure have an API?

No public API is recorded for GliaCure.

What industry is GliaCure in?

GliaCure's product category is Neurological Therapeutics. Its primary akta.pro industry code is HLAKAIAA, General Neurology. Its NAICS code is 54171 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR Newswire18th Annual Conference on Alzheimer's Drug Discovery Showcases Non-Amyloid ResearchNearly 200 academic and industry researchers gathered in New York for the 18th Annual Conference on Alzheimer's Drug Discovery, organized by the Alzheimer's Drug Discovery Foundation, to share updates on non-amyloid drug programs in development. Presentations covered both preclinical and clinical-stage research across targets including neuroinflammation, neuroprotection, neural regeneration, and epigenetics, with several programs advancing toward or through human trials. Companies including GliaCure and M3 Biotechnology highlighted progress on drugs GC021109 and NDX-1017 respectively, while researchers noted growing momentum toward innovative therapeutic targets beyond amyloid-focused approaches.VC News DailyGliaCure Closes on $5.8M FinancingGliaCure, Inc., a Boston-based biopharmaceutical company developing novel non-neuronal therapies for neurological and neuropsychiatric disorders, has successfully completed a $5.8 million B round financing, exceeding its original goal of $5 million. The funding, which includes both existing and new investors, will support the company's upcoming Phase 1 clinical trial for its lead Alzheimer's disease drug candidate GC021109, with the therapy also showing potential for psoriasis, Parkinson's disease, multiple sclerosis, and glaucoma. GliaCure holds an exclusive license to the GC021109 compound and related technology from Tufts University.